Related Articles
Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases
Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer
Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin‑based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials
EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer